uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences

Core Viewpoint - uniQure NV (NASDAQ:QURE) has shown significant stock performance, surging by 17.93% to close at $30.84, driven by investor interest ahead of two healthcare conferences [1][3]. Financial Performance - In the third quarter, uniQure reported a widened net loss of $80.5 million, an increase of 81% from $44.4 million in the same period last year [2][3]. - Total revenues increased by 61% to $3.7 million, up from $2.29 million year-on-year, primarily due to a $1.5 million rise in license revenues, which compensated for a decline in collaboration revenues [3]. Clinical Developments - The company reported positive topline data from a pivotal phase 1/2 study for its AMT-130 treatment candidate for Huntington's disease, showing a 75% slowdown in disease progression without serious adverse reactions [4]. - uniQure is in discussions with the FDA regarding a Biologics License Application, although the agency's response to the results has been lukewarm [4][5]. Upcoming Events - uniQure will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 12 and the Stifel 2025 Healthcare Conference in New York on November 13 [2].